Search results
Showing 106 to 120 of 1521 results for patients and public
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
Involving you in the development of NICE guidance.
Involving you in the development of NICE guidance.
In development Reference number: GID-TA10990 Expected publication date: TBC
In development Reference number: GID-TA10143 Expected publication date: TBC
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
In development Reference number: GID-TA11498 Expected publication date: 29 April 2026
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
In development Reference number: GID-TA11330 Expected publication date: TBC
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis